Epizyme, Inc.
COMBINATION THERAPIES WITH EHMT2 INHIBITORS

Last updated:

Abstract:

The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.

Status:
Application
Type:

Utility

Filling date:

20 Apr 2018

Issue date:

20 Feb 2020